Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers.

Avinoam Nevler Alexander J MullerErika Sutanto-WardJames B DuHadawayKei NagatomoEric LondinKevin O'HayerJoseph A CozzitortoHarish LavuTheresa P YeoMark CurtisTatiana VillatoroBenjamin E LeibyLaura Mandik-NayakJordan M WinterCharles J YeoGeorge C PrendergastJonathan R Brody

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

The results of this study provide genetic support for IDO2 as a contributing factor in PDAC development and argue that IDO2 genotype analysis has the immediate potential to influence the PDAC care decision-making process through stratification of those patients who stand to benefit from adjuvant radiotherapy.

Keyphrases

early stage
decision making
locally advanced
genome wide
radiation therapy
copy number
radiation induced
healthcare
palliative care
late onset
quality improvement
gene expression
rectal cancer
risk assessment
long non coding rna